GlobeNewswire: Motif BioSciences Inc. Contains the last 10 of 80 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:36:11ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/11/26/1952379/0/en/Motif-Bio-plc-Announces-Voluntary-Delisting-from-the-Nasdaq-Capital-Market.html?f=22&fvtc=4&fvtv=30600Motif Bio plc Announces Voluntary Delisting from the Nasdaq Capital Market2019-11-26T07:00:00Z<![CDATA[NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB) ("Motif Bio" or the "Company") announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of the intention to voluntarily delist the Company’s American Depository Shares (ADSs) and listed warrants from the Nasdaq Capital Market. The Company currently anticipates that it will file with the Securities and Exchange Commission (the "SEC") a Form 25, Notification of Removal of Listing and/or Registration Under Section 12(b) the Exchange Act, relating to the delisting and deregistration on or about December 5, 2019, with the delisting of its ADSs and warrants taking effect no earlier than ten days thereafter. As a result, the Company expects that the last trading day of its ADSs and warrants on the Nasdaq Capital Market will be on or about December 16, 2019.]]>https://www.globenewswire.com/news-release/2019/09/02/1909401/0/en/Motif-Bio-and-Hercules-Capital-Amend-Loan-and-Security-Agreement.html?f=22&fvtc=4&fvtv=30600Motif Bio and Hercules Capital Amend Loan and Security Agreement2019-09-02T06:00:00Z<![CDATA[NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that its lender, Hercules Capital, Inc. (“Hercules”), has agreed to amend the Company’s loan and security agreement such that the next amortisation date is postponed from September 1 to October 1, 2019. This change means that the September payment will be interest only. Hercules made this change in support of Motif Bio managing its cash position to advance its pipeline expansion strategy and prepare for the upcoming meeting with the U.S. Food and Drug Administration.]]>https://www.globenewswire.com/news-release/2019/08/19/1903302/0/en/NIH-to-Evaluate-Iclaprim-Activity-against-Listeria.html?f=22&fvtc=4&fvtv=30600NIH to Evaluate Iclaprim Activity against Listeria2019-08-19T06:00:00Z<![CDATA[NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will be utilising NIAID’s1 suite of preclinical services through JMI Laboratories to evaluate iclaprim against Listeria monocytogenes, a Gram-positive bacteria causing food-borne, life-threatening infections. The study, to be funded by NIAID, follows earlier in vitro testing in which iclaprim was ≥32-fold more potent than standard-of-care ampicillin and demonstrated consistent extracellular as well as intracellular activity against L. monocytogenes2.]]>https://www.globenewswire.com/news-release/2019/08/01/1895284/0/en/Motif-Bio-and-Hercules-Capital-Amend-Loan-and-Security-Agreement.html?f=22&fvtc=4&fvtv=30600Motif Bio and Hercules Capital Amend Loan and Security Agreement2019-08-01T06:00:00Z<![CDATA[NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that its Lender, Hercules Capital, Inc., has agreed to amend the Company’s loan and security agreement such that the next amortization date is postponed from August 1 to September 1, 2019. This change means that the August payment will be interest only. Hercules Capital made this change in support of Motif Bio managing its cash runway as it advances its pipeline expansion strategy.]]>https://www.globenewswire.com/news-release/2019/07/26/1892120/0/en/Motif-Bio-Confirms-Meeting-Date-with-U-S-FDA-regarding-Iclaprim.html?f=22&fvtc=4&fvtv=30600Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim2019-07-26T06:00:00Z<![CDATA[NEW YORK, July 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the U.S. Food & Drug Administration (FDA) has granted the Company’s request for a Type B meeting related to a proposed clinical study for the Company’s lead product candidate, iclaprim. The in person meeting has been scheduled for September 19, 2019.]]>https://www.globenewswire.com/news-release/2019/07/26/1892122/0/en/Motif-Bio-Confirms-Receipt-of-Deficiency-Notice-from-Nasdaq.html?f=22&fvtc=4&fvtv=30600Motif Bio Confirms Receipt of Deficiency Notice from Nasdaq2019-07-26T06:00:00Z<![CDATA[NEW YORK, July 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has received a deficiency notice from Nasdaq indicating that, based upon a review of Motif Bio’s trading for the last 30 consecutive business days, the Company no longer meets the minimum bid price rule for continued listing on the Nasdaq Capital Market. Nasdaq Marketplace Rule 5550(a)(2) requires Nasdaq-traded American Depositary Shares (ADSs) to have a minimum bid price of $1.00. Motif Bio previously announced that it was expecting to receive this notification.]]>https://www.globenewswire.com/news-release/2019/07/19/1885110/0/en/Motif-Bio-Announces-Receipt-of-Deficiency-Notice-from-Nasdaq.html?f=22&fvtc=4&fvtv=30600Motif Bio Announces Receipt of Deficiency Notice from Nasdaq2019-07-19T06:00:00Z<![CDATA[NEW YORK, July 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has received a deficiency notice from Nasdaq indicating that, based upon a review of Motif Bio’s Market Value of Listed Securities (MVLS) for the last 30 consecutive business days, the Company no longer meets the minimum MVLS standard for continued listing on the Nasdaq Capital Market as set forth in Nasdaq Marketplace Rule 5550(b)(2), which requires the Company to have a minimum MVLS of $35 million.]]>https://www.globenewswire.com/news-release/2019/07/15/1882340/0/en/Motif-Bio-Submits-Meeting-Request-and-Package-to-the-U-S-FDA-for-Iclaprim.html?f=22&fvtc=4&fvtv=30600Motif Bio Submits Meeting Request and Package to the U.S. FDA for Iclaprim2019-07-15T06:00:00Z<![CDATA[NEW YORK, July 15, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has submitted a meeting request and package to the U.S. Food & Drug Administration (FDA) related to the Company’s lead product candidate, iclaprim. In the minutes from a May 3, 2019, Type A meeting, the FDA indicated that an additional clinical trial will be required prior to granting marketing approval of iclaprim. The Company has been encouraged by the FDA to put forth a proposal for such a study. Motif Bio has requested a Type B meeting with the Agency to discuss the proposed study population and design. The Company will provide guidance on when such a meeting will occur once FDA issues the meeting granted letter. The FDA typically schedules a Type B meeting within 60 days of request, although it can take longer.]]>https://www.globenewswire.com/news-release/2019/06/24/1872724/0/en/Motif-Bio-Presents-New-Iclaprim-Data-at-ASM-Microbe-2019.html?f=22&fvtc=4&fvtv=30600Motif Bio Presents New Iclaprim Data at ASM Microbe 20192019-06-24T06:00:00Z<![CDATA[NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today reported that new iclaprim data were presented at the American Society For Microbiology (ASM) Microbe 2019 meeting held in San Francisco, CA, USA, June 20-24, 2019.]]>https://www.globenewswire.com/news-release/2019/06/06/1865079/0/en/Motif-Bio-Announces-Path-Forward-for-Iclaprim-following-Receipt-of-FDA-Meeting-Minutes.html?f=22&fvtc=4&fvtv=30600Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes2019-06-06T06:00:00Z<![CDATA[Conference call scheduled for Thursday, June 6, 2019 at 8:00 AM EDT/1:00 PM BST/2:00 PM CET Conference call scheduled for Thursday, June 6, 2019 at 8:00 AM EDT/1:00 PM BST/2:00 PM CET]]>